Updates in the Management of Stage III Non-Small Cell Lung Cancer (NSCLC) - Episode 6

Management of Resectable Early Stage NSCLC with Actionable Mutations

, , ,

The panel discusses management of resectable early-stage non–small cell lung cancer.

EP. 1: Patient with Stage IIIB NSCLC with No Actionable Mutations and PD-L1 TPS 0%
EP. 2: Biomarker Testing and the Multidisciplinary Approach in Early-Stage NSCLC
EP. 3: Navigating Neoadjuvant and Perioperative Treatment Strategies in Early Stage NSCLC
EP. 4: Treatment Considerations for Neoadjuvant and Perioperative Therapy in ES NSCLC
EP. 5: Management of Borderline Resectable NSCLC
Now Viewing
EP. 6: Management of Resectable Early Stage NSCLC with Actionable Mutations
EP. 7: Considerations for Combination of Adjuvant Chemotherapy and Targeted Therapy in Resectable ES NSCLC
EP. 8: Patient with Unresectable Stage IIIB EGFR-Mutant NSCLC with N2 Bulky Disease
EP. 9: Expert Perspectives on Patient Selection for cCRT and sCRT in Unresectable ES NSCLC
EP. 10: Treatment Considerations for Consolidation Durvalumab in Unresectable ES NSCLC

Video content above is prompted by the following:

How does your approach differ based on PD-L1 status? Presence of EGFR/ALK alterations?